GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

GlaxoSmithKline (GSK.L) is taking its fight with Gilead Sciences (GILD.O) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.